Precision Medicine

Targeting Exon 20 Mutations in NSCLC

Charu Aggarwal, MD, MPH; Lyudmila Bazhenova, MD
The Increasing Role of Dual Immunotherapy in mNSCLC Patients

Biagio Ricciuti, MD, PhD
Ready for RAS Beyond G12C

Charu Aggarwal, MD, MPH; Biagio Ricciuti, MD, PhD
The Evolving Approach to Management of Stage IV EGFRm NSCLC

Charu Aggarwal, MD, MPH
Approach to Management of ROS1m NSCLC

Charu Aggarwal, MD, MPH
Integrating NORTHSTAR/COMPEL Into Clinical Practice: A Tumor Board Focused on Duration of Osimertinib Therapy

Zofia Piotrowska, MD, MHS; Charu Aggarwal, MD, MPH
Post ASCO Update on Management of HER2+ Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Tanios S. Bekaii-Saab, MD
ASCO Update: Adjuvant RET Directed Therapy in NSCLC

Charu Aggarwal, MD, MPH; Jonathan W Goldman, MD
ASCO Update: Daraxonrasib (RMC-6236) for KRAS mutated metastatic pancreatic cancer

John Strickler, MD; Tanios S. Bekaii-Saab, MD
An Update on the role of ctDNA-MRD Assessment in The Management of Breast Cancer

Jason A. Mouabbi, MD
Importance of NGS testing for STK11 and KEAP1 mutation and impact on treatment selection

Charu Aggarwal, MD, MPH; Biagio Ricciuti, MD, PhD
What is the optimal approach to targeting BRAF V600E, HER2 overexpression, and KRAS G12C in patients with metastatic CRC?

John Strickler, MD